Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;25(4):679-85.
doi: 10.1007/s00467-009-1432-2. Epub 2010 Jan 27.

Growth and body composition in very young SGA children

Affiliations
Review

Growth and body composition in very young SGA children

Jesús Argente et al. Pediatr Nephrol. 2010 Apr.

Abstract

Infants with a very low birth weight are at risk of a reduced number of nephrons predisposing to kidney disorder, hypertension, and metabolic syndrome. Approximately 3% of infants are born small for gestational age (SGA), defined as birth weight and/or length at least 2 SD below the mean for gestational age (GA), independently of whether these children are born prematurely or at term. About 10% of these children do not show postnatal catch-up growth and remain of short stature during childhood. Most of these infants are not growth hormone (GH)-deficient, but may have GH resistance. Although GH-resistant, the majority of patients benefit from GH therapy, normalize height during childhood, maintain a normal growth velocity during puberty, and attain a normal adult height. To date, GH has been shown to be safe and no significant adverse effects have been demonstrated. Children with congenital chronic kidney disease (CKD) are born with subnormal birth weight and length and about 25% are born SGA. Shortness and need for GH treatment is highly correlated with weight at birth and gestational age. Primary renal disorders modify the response to GH treatment. Analysis of whether SGA is an additional risk factor for CKD regarding the development of hypertension, metabolic syndrome and cardiovascular complications is required.

PubMed Disclaimer

References

    1. J Pediatr. 2006 Jun;148(6):747-52 - PubMed
    1. N Engl J Med. 2003 Dec 4;349(23):2211-22 - PubMed
    1. Pediatr Res. 1990 Jul;28(1):5-10 - PubMed
    1. Pediatr Res. 1988 Sep;24(3):380-3 - PubMed
    1. J Clin Endocrinol Metab. 2001 Jan;86(1):267-72 - PubMed

MeSH terms

Substances

LinkOut - more resources